SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Samrat Pharmachem informs about press release

18 Sep 2023 Evaluate
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, Samrat Pharmachem has informed that it enclosed copy of newspaper publication of Corrigendum on Record Date for payment of Dividend and Revision of Book Closure Date. The Corrigendum Notice was published in the following newspapers on September 16, 2023. Indian Express (In English, Vadodara Edition); Vadodara Samachar (In Gujarati, Vadodara Edition).

The above information is a part of company’s filings submitted to BSE.

Samrat Pharmachem Share Price

226.00 4.85 (2.19%)
22-Apr-2026 13:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1664.90
Dr. Reddys Lab 1225.40
Cipla 1235.00
Zydus Lifesciences 929.20
Lupin 2314.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×